IL22 and adenoma: The similarity in the tissue pathology during hyperplasia (4–6 weeks) and adenoma/MIN (6–8 weeks) between IL‐22+/+ and IL‐22−/−/PyMT mice was also confirmed by Ki‐67 cell proliferation marker staining.